Skip to main content
Fig. 2 | Experimental Hematology & Oncology

Fig. 2

From: Adefovir dipivoxil inhibits APL progression through degradation of the oncoprotein PML-RARA

Fig. 2

The western blot analysis and RNA-seq results in vitro. A Western blot results of PARP, cleaved PARP, mTOR, p-mTOR, PML-RARA, PML, and TRIB3 level in NB4 or HL-60 cells after treatment with 5 µM ADV for 24 h, or 5 µM ETV for 48 h. In NB4 cells, the relative protein density ratio of cleaved PARP to GAPDH in ADV group is much higher than that in control group (7.37:1), and the relative protein density ratio of p-mTOR to GAPDH in ADV group is slightly lower than that in control group (0.79:1). B Volcano plots showing differentially expressed genes for NB4 cells after treatment with 5 µM ADV for 24 h. C Heat map of TOP50 differentially expressed genes in NB4 cells after treatment with 5 µM ADV for 24 h compared to control (with DMSO only). Each row represents one differentially expressed gene; each column represents one sample. Z-scores are calculated for each row (each gene) and these are plotted instead of the normalized expression values. D KEGG pathway analysis of downregulated genes and upregulated genes. Count is the number of DEGs in the given KEGG term, padj is the p-value adjusted for multiple testing, and gene ratio indicates the ratio of the number of DEGs annotated to a KEGG pathway to the total number of DEGs. E At 24 h after treatment with 5 µM ADV. RNA-sequencing was conducted in 3 independent experiments with similar results

Back to article page